Do we need oxytocin to treat schizophrenia? A randomized clinical trial

Jessica Dagani, Davide Sisti, Marianna Abelli, Luca Di Paolo, Stefano Pini, Sara Raimondi, Marco B. Rocchi, Francesco M. Saviotti, Paolo Scocco, Stefano Totaro, Matteo Balestrieri, Giovanni de Girolamo

Research output: Contribution to journalArticlepeer-review


Background: Schizophrenia is a disabling complex mental disorder and despite all available treatment, many patients unfortunately remain partial- or non-responders. A large body of research has shown that oxytocin is an important prosocial peptide and there is initial evidence that the central oxytocin system is altered in several mental disorders. The aim of this study was to test the efficacy of oxytocin, as augmentation therapy, in a sample of patients with schizophrenia. Methods: We conducted an 8-month randomized, double-blind, controlled trial with a crossover design. We wanted to test the hypothesis that intranasal oxytocin could reduce symptoms in 32 patients with schizophrenia aged 18-45 with short-medium illness duration (

Original languageEnglish
Pages (from-to)158-164
JournalSchizophrenia Research
Issue number1-3
Publication statusPublished - Apr 2016

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Do we need oxytocin to treat schizophrenia? A randomized clinical trial'. Together they form a unique fingerprint.

Cite this